HONG KONG – Singapore's Aslan Pharmaceuticals Ltd. and South Korea's Bukwang Pharmaceutical Co. Ltd. have jointly established a new company dedicated to the development of aryl hydrocarbon receptor (AhR) drug candidates. Named Jaguahr Therapeutics Pte. Ltd. – the unusual spelling a clear reference to "AhR" – it will be based in Singapore and will focus on developing immuno-oncology therapeutics for global markets based on the preclinical AhR antagonists in Aslan's early stage pipeline.

CEO Mark McKenna told BioWorld Asia that San Diego-based Prometheus Biosciences Inc. has "cracked the code" in inflammatory bowel disease (IBD) – progress underscored by the firm's deal with Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, which brings an undisclosed up-front payment and as much as $420 million more if development, regulatory and commercial milestones are reached in three programs.

HONG KONG – South Korean biotech Bioleaders Co. Ltd., headquartered in Yong-in city, Gyeonggi-do, and Israel's Weizmann Institute of Science, based in Rehovot, recently founded a joint venture in Israel. With the new entity, they will accelerate the R&D of a Weizmann-developed approach targeting p53, a strong tumor suppressor that has proved difficult to drug.

Akcea Therapeutics Inc., a majority owned affiliate of Ionis Pharmaceuticals Inc., and Pfizer Inc. signed an exclusive, worldwide licensing deal for AKCEA-ANGPTL-3-LRx, which is being developed to treat cardiovascular and metabolic diseases. The deal follows a period during which Akcea's stock (NASDAQ:AKCA) has sagged prior to rising Monday and big changes in the company's C-suite.

HONG KONG – South Korean biotech Bioleaders Co. Ltd., headquartered in Yong-in city, Gyeonggi-do, and Israel's Weizmann Institute of Science, based in Rehovot, recently founded a joint venture in Israel. With the new entity, they will accelerate the R&D of a Weizmann-developed approach targeting p53, a strong tumor suppressor that has proved difficult to drug.

CEO Mark McKenna told BioWorld that San Diego-based Prometheus Biosciences Inc. has "cracked the code" in inflammatory bowel disease (IBD) – progress underscored by the firm's deal with Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, which brings an undisclosed up-front payment and as much as $420 million more if development, regulatory and commercial milestones are reached in three programs.

Angiodynamics Inc., of Latham, N.Y., is picking up Rehovot, Israel-based Eximo Medical Ltd. for $46 million up front and up to $20 million of contingent consideration related to certain technical and revenue milestones. Eximo offers laser atherectomy technology that is in a limited launch.

Newlink Genetics Corp. and Lumos Pharma Inc. have agreed to merge, with the deal expected to close in the first quarter of 2020. Lumos will become a wholly owned subsidiary of Newlink, which will be renamed Lumos Pharma Inc.

The diversification at Swedish Orphan Biovitrum AB (Sobi) continued Monday with its acquisition of Dova Pharmaceuticals Inc. in a deal worth about $915 million.

BOSTON – How are med-tech companies reacting to the findings of the EY Pulse of the Industry report 2019? Members of a panel examined this question this week during the Medtech Conference in Boston, while also offering their insight on where the industry is headed.